| Dr Peter Stuart Johnson, MD | |
|
1600 S Andrews Avenue, Broward General Medical Center, Fort Lauderdale, FL 33316 | |
| (954) 355-5589 | |
| Not Available |
| Full Name | Dr Peter Stuart Johnson |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 1600 S Andrews Avenue, Fort Lauderdale, Florida |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003872607 | NPI | - | NPPES |
| 068175000 | Medicaid | FL | |
| 94119 | Other | FL | BCBS OF FL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | ME035836 (Florida) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Stuart Johnson, MD Po Box 890, Bluefield, WV 24701-0890 Ph: () - | Dr Peter Stuart Johnson, MD 1600 S Andrews Avenue, Broward General Medical Center, Fort Lauderdale, FL 33316 Ph: (954) 355-5589 |
News Archive
Even low doses of Ecstasy may be associated with a decline in language-related memory, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.
Quality of life for disabled elderly people is most closely tied to two factors: a sense of dignity and a sense of control, according to a study by researchers at the San Francisco VA Medical Center (SFVAMC) and the University of California, San Francisco.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
Alexza Pharmaceuticals, Inc. today announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA).
Department of Defense Secretary Robert Gates on Friday announced the creation of an independent panel to examine outpatient conditions at Walter Reed Army Medical Center and other military hospitals, the Los Angeles Times reports (Barnes, Los Angeles Times, 2/24).
› Verified 3 days ago
Alexandra Jimenez, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 60 Compass Is, Fort Lauderdale, FL 33308 Phone: 954-661-4552 Fax: 954-938-2532 | |
Marie Juste, Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Sw 31st Ave, Fort Lauderdale, FL 33312 Phone: 954-357-5200 | |
Abigail L Alexander, MD, MPH Pathology Medicare: Not Enrolled in Medicare Practice Location: 5301 Sw 31st Ave, Fort Lauderdale, FL 33312 Phone: 954-357-5200 | |
Farhad Askarian, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1600 S Andrews Ave, Fort Lauderdale, FL 33316 Phone: 954-355-5569 Fax: 954-355-5568 | |
Prof. Ramila H Gavan, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 6401 N Federal Hwy, Fort Lauderdale, FL 33308 Phone: 954-776-8500 | |
Dr. Valerie Ann Lyons, M.D.,FCAP Pathology Medicare: Not Enrolled in Medicare Practice Location: 52 Royal Palm Dr, Fort Lauderdale, FL 33301 Phone: 954-895-1081 Fax: 954-895-1081 |